Despite a trend toward more patient-centered research, quality-of-life end points remain substantially underreported in phase ...
An international, randomized, double-blind, placebo-controlled Phase III study—the largest of its kind for mpox—found that tecovirimat did not improve clinical outcomes for adults with clade II mpox ...
As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...
Systematic review shows GLP 1 receptor agonists trials rarely assess dietary intake, highlighting a major evidence gap in nutrition outcomes.
Remote clinical pharmacist impact on reducing total cost of care in Enhancing Oncology Model–enrolled oncology practices. Electronic patient-reported outcome-based weight management versus usual care ...
When Elise Felicione tried to design a clinical trial for a supplement, 5 things got in the way. It’s a lesson for the ...
Early clinical trials established the safety and feasibility of closed-loop insulin delivery, but the 2019 iDCL trial1 marked the first large, outpatient, randomised, controlled trial to show a ...
We preselected all newsletters you had before unsubscribing.
Clinical trials can vary in length depending on several factors. Here's what you need to know about how long clinical trials last.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results